What Is Alkaline Phosphatase (ALP)? Normal vs Optimal Range Explained

The standard reference range of 44–147 U/L was calibrated across a broad population that includes growing adolescents, pregnant women, and older adults with subclinical bone loss—all groups with physiologically elevated ALP that skew the upper boundary. For a non-growing adult who isn't pregnant, an ALP of 130 U/L is technically "normal" but already suggests either bile duct dysfunction or accelerated bone turnover that warrants further investigation. The human body expresses at least four distinct ALP isoenzymes—liver/bone/kidney (tissue-nonspecific), intestinal, placental, and germ cell—each encoded by separate genes on different chromosomes. The CTD records over 1,400 compound–gene interactions for the ALP family of isoenzymes, showing how profoundly medications and environmental exposures influence this enzyme across all tissue sources. ALP above 100 U/L in a healthy adult should trigger a GGT test: if GGT is also elevated, the ALP source is hepatobiliary; if GGT is normal, the source is bone. This single follow-up test transforms an ambiguous result into a clear clinical direction.

PubMed indexes over 45,000 publications involving alkaline phosphatase, spanning liver disease, bone metabolism, cardiovascular risk assessment, and oncologic staging. One consistent finding across large cohorts is that ALP in the upper third of the normal range independently predicts cardiovascular events—a connection that likely reflects underlying inflammation, endothelial dysfunction, and vascular calcification rather than liver or bone disease specifically. ALP directly participates in vascular calcification by hydrolyzing pyrophosphate, the body's natural inhibitor of calcium deposition in arterial walls. FAERS pharmacovigilance data document ALP elevation as a reported adverse event for over 200 commonly prescribed medications, including anticonvulsants, antibiotics, immunosuppressants, and proton pump inhibitors. When ALP rises during drug therapy, the first clinical question is whether the medication is causing direct cholestatic liver injury or indirectly raising bone-fraction ALP through vitamin D depletion and secondary hyperparathyroidism.

On the low end, ALP below 40 U/L is underrecognized but clinically meaningful. ALP is a zinc-dependent metalloenzyme that also requires magnesium for full catalytic activity, so unexpectedly low ALP may serve as a functional marker of zinc or magnesium depletion—an insight rarely captured by standard lab interpretation. Hypothyroidism, pernicious anemia, and cardiac bypass surgery can also suppress ALP activity through distinct mechanisms. In rare cases, persistently very low ALP below 20 U/L points to hypophosphatasia, a genetic condition affecting approximately 1 in 100,000 adults that impairs bone mineralization due to loss-of-function mutations in the tissue-nonspecific ALP gene (ALPL). Bone (PMID 28159710) provides a comprehensive clinical overview of this underdiagnosed condition. Targeting the 40–100 U/L optimal band means your liver bile ducts are clear, your bone turnover is balanced, and your zinc and magnesium cofactors are adequate—a metabolic snapshot that many providers overlook.